Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients
- 2 January 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (1) , 35-40
- https://doi.org/10.1097/01.aids.0000196179.11293.fc
Abstract
To develop a clinically relevant genotypic resistance score for boosted atazanavir (ATV) in protease inhibitor-experienced patients. At baseline, 62 patients with HIV-1 RNA > 1000 copies/ml switched to a boosted ATV regimen (300 mg ATV, 100 mg ritonavir once daily); two were excluded from analysis at 3 months as they had undetectable plasma ATV. The impact of baseline protease mutations on virological response (> 1 log10 copies/ml plasma HIV RNA decrease) at 3 months was analysed using Fisher's exact test. Mutations with prevalence > 8% and P At 3 months, 82% of patients had a virological response and 56% had RNA P The occurrence of three of the eight mutations in the ATV/RTV genotypic resistance score predicted a clinically identifiable reduced response in patients.Keywords
This publication has 20 references indexed in Scilit:
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failuresAIDS, 2005
- Comparison of Once-Daily Atazanavir With Efavirenz, Each in Combination With Fixed-Dose Zidovudine and Lamivudine, As Initial Therapy for Patients Infected With HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Atazanavir: New Option for Treatment of HIV InfectionClinical Infectious Diseases, 2004
- Identification of I50L as the Signature Atazanavir (ATV)–Resistance Mutation in Treatment‐Naive HIV‐1–Infected Patients Receiving ATV‐Containing RegimensThe Journal of Infectious Diseases, 2004
- Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjectsAIDS, 2003
- Activities of Atazanavir (BMS-232632) against a Large Panel of Human Immunodeficiency Virus Type 1 Clinical Isolates Resistant to One or More Approved Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2003
- Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Acute HIV infection: impact on the spread of HIV and transmission of drug resistanceAIDS, 2001
- Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1999
- THE COMPARISON OF PERCENTAGES IN MATCHED SAMPLESBiometrika, 1950